e-learning
resources
European Respiratory Review
2008
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy
Horvath Gabor, Mendes Eliana S., Schmid Nathalie, Schmid Andreas, Conner Gregory E., Salathe Matthias, Wanner Adam
Source:
Eur Respir Rev 2008; 17: 41-42
Journal Issue:
April 2008 - 17 (107)
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Horvath Gabor, Mendes Eliana S., Schmid Nathalie, Schmid Andreas, Conner Gregory E., Salathe Matthias, Wanner Adam. Rapid corticosteroid effect on long-acting β2-agonist disposal by smooth muscle cells in the airway: a new paradigm of inhaled combination therapy. Eur Respir Rev 2008; 17: 41-42
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Interactions of pharmacotherapy and exercise training
Comparison of bronchodilator responsiveness in children with primary ciliary dyskinesia and cystic fibrosis
Reproducibility of inhaler use and pulmonary drug deposition in COPD
Related content which might interest you:
Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β
2
-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells
Source: Eur Respir J 2003; 22: Suppl. 45, 35s
Year: 2003
Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007
Carrier-mediated disposal mechanisms for long-acting β
2
-agonists in the airway: the emerging role of corticosteroid sensitivity
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD
Year: 2008
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006
Bronchodilator activity of the combination of salbutamol hemisuccinate and methatropium iodide compared with monotherapy in preclinical studies
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment
Source: Eur Respir J 2008; 31: 1145-1147
Year: 2008
The concept study: comparative influence of two treatment strategies on airway response to AMP
Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how?
Year: 2005
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma
Source: Eur Respir J 2006; 27: 172-187
Year: 2006
Effects of intervention with high-dose inhaled corticosteroids on airway remodelling in diagnosed genetic variants of
IL13
with asthma
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
The long-acting β2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC)
Source: Annual Congress 2011 - Understanding disease and drug mechanisms
Year: 2011
Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model
Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases
Year: 2021
Inhaled budesonide induces corticosteroid-dependent gene expression in asthmatics: Validation in primary epithelial and airways smooth muscle cells
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011
Refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β
2
agonist inhalation: is this phenomenon airway remodeling?
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001
Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Pharmacological characterization of CHF6162, a novel long acting inhaled corticosteroid for the treatment of asthma
Source: International Congress 2017 – Novel mechanisms and treatments for asthma
Year: 2017
Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept